Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals puts another potential treatment in the pot

GW Pharmaceuticals puts another potential treatment in the pot

Cannabis-based drug maker GW Pharmaceuticals (LON:GWP) has potentially added a new treatment to its development pipeline following a positive outcome in a university research programme.

The research carried out at Reading University, and part funded by GW, has demonstrated for the first time that a previously unstudied chemical present in cannabis, called cannabidivarin (or CBDV)  could lead to more effective treatment for people with epilepsy.

In the study the chemical strongly suppressed seizures, GW said.

GW already has already developed and commercialised a cannabis based treatment – in the form of a spray – for people suffering from multiple sclerosis. And it continues to explore other potential treatments.

"These results further underscore the potential of naturally-derived cannabinoids as medicines to treat a broad range of diseases,” said Dr Stephen Wright, GW Pharmaceuticals’ director of research and development. 

“GW has established a track record of discovering and commercialising such compounds with Sativex®now on the market for treating spasticity associated with multiple sclerosis and in late stage development for the treatment of cancer pain. 

“Our research into CBDV has consistently produced highly promising results demonstrating its potential as a novel anticonvulsant and GW hopes during 2013 to advance CBDV into human clinical trials."


Join our Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

October 10 2018
Management behind ICC International Cannabis Corp has a clear buy, build and sell strategy
medical cannabis
October 01 2018
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.
Cannabis leaf
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use